logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
L

Li-Tzong Chen

kaohsiung medical university
H指数:55
被引数:1.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

SLOG versus Modified FOLFIRINOX as First-Line Treatment for Advanced Pancreatic Cancer: A Randomized Phase II Trial (TCOG T5217)

SLOG与改良FOLFIRINOX作为晚期胰腺癌一线治疗的比较：一项随机II期临床试验（TCOG T5217）

European Journal of Cancer
IF7.1
2026-01-110
PRE
Nai-Jung Chiang; Yung-Yeh Su; I-Wei Ho; Li-Yuan Bai; Chung-Pin Li; Jen-Shi Chen; Chin-Fu Hsiao; Hsiao-Hui Tsou; Chiun Hsu; Tai-Jan Chiu; Yao-Yu Hsieh; Kun-Ming Rau; Ching-Liang Ho; Yan-Shen Shan; Li-Tzong Chen
A phase I/II study using cabozantinib and lanreotide as treatments for advanced GEP-NETs for which molecular targeted therapy or chemotherapy have failed (SCALET): TCOG T2221 study

I/II期研究使用卡博替尼和兰瑞肽治疗分子靶向治疗或化疗失败的晚期GEP-NETs（SCALET）：TCOG T2221研究

ESMO Open
IF8.3
2026-01-010
OA
Hui‐Jen Tsai; Ming‐Huang Chen; Chin‐Fu Hsiao; L.-Y. Bai; Y.-Y. Chen; W.-C. Chou; Yung‐Yeh Su; M.-S. Dai; Y.-H. Liang; Y.-S. Shan; Chia‐Jui Yen; Tsung‐Hao Liu; J.-S. Chen; C.-Y. Yang; Chih‐Chieh Yen; J.-S. Chen; H.-C. Hsu; Yu‐Li Su; Chia‐Hsun Hsieh; Li‐Tzong Chen
Second-line 5-FU plus nanoliposomal irinotecan versus FOLFOX/XELOX in metastatic pancreatic cancer after gemcitabine–nab-paclitaxel failure: a propensity score-matched analysis

二线5-FU联合纳米脂质体伊立替康与FOLFOX/XELOX方案对比：在吉西他滨–白蛋白结合型紫杉醇治疗失败后的转移性胰腺癌中的倾向性评分匹配分析

ESMO Open
IF8.3
2025-11-070
OAAI
G. Trovato; D. Rossini; A. Guidolin; Y.-Y. Su; Y.-S. Shan; N.-J. Chiang; W.-C. Chou; L.-Y. Bai; C. Bagalà; M. Bensi; M. Niger; S. Marchesi; S.K. Garattini; A. Michelotti; A. Pretta; M. Scartozzi; C. Vivaldi; L. Bartalini; L. Procaccio; F. Bergamo; L. Antonuzzo; L.-T. Chen; L. Salvatore; G. Tortora
Nanoliposomal Irinotecan in Combination With 5-Fluorouracil and Leucovorin for Advanced Head and Neck and Esophageal Squamous Cell Carcinoma After Prior Platinum-Based Chemotherapy or Chemoradiotherapy: A Multicenter Phase II Trial

纳米脂质体伊立替康联合5-氟尿嘧啶和亚叶酸钙用于经前期铂类为基础的化疗或放化疗后的晚期头颈及食管鳞状细胞癌：一项多中心II期临床试验

Cancer Medicine
IF3.1
2025-10-210
OAAI
Muh-Hwa Yang; Shang-Yin Wu; I-Wei Ho; Nai-Jung Chiang; Chin-Fu Hsaio; Chen-Yuan Lin; Ming-Yu Lien; Peter Mu-Hsin Chang; Jia-Hong Chen; Ching-Yun Hsieh; Ruey-Long Hong; Chao-Tung Lee; Li-Tzong Chen; Tsang-Wu Liu; Chang-Fang Chiu; Li-Yuan Bai
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with pancreatic cancer

泛亚洲适应性ESMO临床实践指南：胰腺癌患者的诊断、治疗和随访

ESMO Open
IF8.3
2025-10-090
OAAI
D. Tai; T. Conroy; J.J.X. Lee; C.E. Chee; C.-Y. Hao; I. Wijaya; S. Aggarwal; M. Ueno; H.-C. Jeung; N.M. Hashim; J. Tan Chun Bing; L.-T. Chen; K. Korphaisarn; S. Tanasanvimon; W.-C. Chou; E. Cargullo; N.F.A. Muin; M.A. Lee; A. Ohba; S. Bondarde; C.R.A. Lesmana; L. Wang; E.C. Smyth; T. Yoshino; G. Bonney; G. Pentheroudakis; J. Samol; A. Cervantes; E. Poon; M. Ducreux
Taiwan liver cancer association management consensus guidelines for intermediate-stage hepatocellular carcinoma

台湾肝癌协会关于中晚期肝细胞癌的管理共识指南

CLINICAL AND MOLECULAR HEPATOLOGY
IF16.9
2025-10-011
OAAI
Lee, I-Cheng; Wang, Hung-Wei; Teng, Wei; Lin, Tsung-Jung; Chen, Chien-Hung; Lai, Hsueh-Chou; Lee, Teng-Yu; Chang, Ching-Wei; Hung, Chao-Hung; Dai, Chia-Yen; Hung, Yi-Ping; Shen, Ying-Chun; Su, Chien-Wei; Ho, Ming-Chih; Lee, Wei-Chen; Chau, Gar-Yang; Ting, Chin-Tsung; Liang, Po-Chin; Liu, Chien-An; Chang, Pi-Yi; Chen, Kuan-Yang; Lin, Shi-Ming; Chen, Li-Tzong; Huang, Yi-Hsiang
Clinical outcomes of gastroenteropancreatic neuroendocrine neoplasms in Taiwan: A multicenter registry study—TCOG T1214 study

台湾地区胃肠胰神经内分泌新生物的临床结局：一项多中心登记研究—TCOG T1214研究

Cancer
IF5.1
2025-08-200
OAAI
Hui-Jen Tsai MD PhD; Ming-Huang Chen MD PhD; Hsiu-Po Wang MD; Chin-Fu Hsiao PhD; Yen-Yang Chen MD PhD; Jen-Shi Chen MD; Mei-Due Yang MD PhD; Chin-Yuan Tzen MD PhD; Yan-Shen Shan MD PhD; Li-Yaun Bai MD PhD; De-Chuan Chan MD; Pei-Yi Chu MD PhD; Ching-Liang Ho MD; Youngsen Yang MD; Johnson Lin MD; Hsuan-Yu Lin MD; Cheng-Shyong Chang MD; Chuan-Cheng Wang MD; Tsann-Long Hwang MD; Li-Tzong Chen MD PhD
Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study

度伐鲁单抗联合化疗在晚期胆道癌中的应用：III期TOPAZ-1研究的3年总生存期更新

Journal of Hepatology
IF33
2025-05-150
OAAI
Do-Youn Oh; Aiwu Ruth He; Shukui Qin; Li-Tzong Chen; Takuji Okusaka; Jin Won Kim; Thatthan Suksombooncharoen; Myung Ah Lee; Masayuki Kitano; Howard A. Burris; Mohamed Bouattour; Suebpong Tanasanvimon; Renata Zaucha; Antonio Avallone; Juan Cundom; Aleksandra Kuzko; Julie Wang; Ioannis Xynos; Arndt Vogel; Juan W. Valle
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer (vol 9, 103647, 2024)
ESMO OPEN
IF8.3
2025-01-010
OAAI
Chen, L. -T.; Vogel, A.; Hsu, C.; Chen, M. -H.; Fang, W.; Pangarsa, E. A.; Sharma, A.; Ikeda, M.; Park, J. O.; Tan, C. K.; Regala, E.; Tai, D.; Tanasanvimon, S.; Charoentum, C.; Chee, C. E.; Lui, A.; Sow, J.; Oh, D. -Y.; Ueno, M.; Ramaswamy, A.; Jeo, W. S.; Zhou, J.; Curigliano, G.; Yoshino, T.; Bai, L. -Y.; Pentheroudakis, G.; Chiang, N. -J.; Cervantes, A.; Chen, J. -S.; Ducreux, M.
Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trial

Nivolumab联合化疗治疗HER2-negative，既往未治疗，不可切除，晚期或复发性胃/胃食管交界癌患者: 吸引-4随机，双盲，安慰剂对照，3期临床试验的3年随访

GASTRIC CANCER
IF5.1
2024-08-201
OAAI
Boku, Narikazu; Omori, Takeshi; Shitara, Kohei; Sakuramoto, Shinichi; Yamaguchi, Kensei; Kato, Ken; Kadowaki, Shigenori; Tsuji, Kunihiro; Ryu, Min-Hee; Oh, Do-Youn; Oh, Sang Cheul; Rha, Sun Young; Lee, Keun-Wook; Chung, Ik-Joo; Sym, Sun Jin; Chen, Li-Tzong; Chen, Jen-Shi; Bai, Li-Yuan; Nakada, Takashi; Hagihara, Shunsuke; Makino, Reina; Nishiyama, Eiji; Kang, Yoon-Koo
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer

泛亚适应ESMO临床实践指南，用于胆道癌患者的诊断，治疗和随访

ESMO OPEN
IF8.3
2024-08-010
OAAI
Chen, L. -T; Vogel, A.; Hsu, C.; Chen, M. -h.; Fang, W.; Pangarsa, E. A.; Sharma, A.; Ikeda, M.; Park, J. O.; Tan, C. K.; Regala, E.; Tai, D.; Tanasanvimon, S.; Charoentum, C.; Chee, C. E.; Lui, A.; Sow, J.; Oh, D. -y.; Ueno, M.; Ramaswamy, A.; Jeo, W. S.; Zhou, J.; Curigliano, G.; Yoshino, T.; Bai, L. -y.; Pentheroudakis, G.; Chiang, N. -j.; Cervantes, A.; Chen, J. -s.; Ducreux, M.
Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1) : updated overall survival from a randomised phase 3 study
LANCET GASTROENTEROLOGY & HEPATOLOGY
IF38.6
2024-08-0115
PRE
Oh, Do-Youn; He, Aiwu Ruth; Bouattour, Mohamed; Okusaka, Takuji; Qin, Shukui; Chen, Li-Tzong; Kitano, Masayuki; Lee, Choong-kun; Kim, Jin Won; Chen, Ming -Huang; Suksombooncharoen, Thatthan; Ikeda, Masafumi; Lee, Myung Ah; Chen, Jen-Shi; Potemski, Piotr; Burris, Howard A.; Ostwal, Vikas; Tanasanvimon, Suebpong; Morizane, Chigusa; Zaucha, Renata E.; Mcnamara, Mairead G.; Avallone, Antonio; Cundom, Juan E.; Breder, Valeriy; Tan, Benjamin; Shimizu, Satoshi; Tougeron, David; Evesque, Ludovic; Petrova, Mila; Zhen, David B.; Gillmore, Roopinder; Gupta, Vineet Govinda; Dayyani, Farshid; Park, Joon Oh; Buchschacher Jr, Gary L.; Rey, Felipe; Kim, Hyosung; Wang, Julie; Morgan, Claire; Rokutanda, Nana; Zotkiewicz, Magdalena; Vogel, Arndt; Valle, Juan W.
Survival of advanced/recurrent gastrointestinal stromal tumors treated with tyrosine kinase inhibitors in Taiwan: a nationwide registry study
BMC CANCER
IF3.4
2024-07-110
OAAI
Tsai, Hui-Jen; Shan, Yan-Shen; Yang, Ching-Yao; Hsiao, Chin-Fu; Tsai, Chung-Hsin; Wang, Chuan-Cheng; Lin, Ming-Tsan; Ting, Chun-Fu; Chan, De-Chuan; Chen, Te-Hung; Yen, Chueh-Chuan; Chen, Yen-Yang; Lin, Hsuan-Yu; Yeh, Ta-Sen; Ho, Ching-Liang; Shieh, Tze-Yu; Bai, Li-Yaun; Hsu, Jun-Te; Chen, I-Shu; Chen, Li-Tzong; Yeh, Chun-Nan; Liu, Tsang-Wu; Chuang, Chieh-Han; Wang, Tsang-En
Plain language summary of the FOENIX-CCA2 study: futibatinib for people with advanced bile duct cancer

FOENIX-CCA2研究的简明语言摘要: futibatinib用于晚期胆管癌患者

FUTURE ONCOLOGY
IF2.6
2024-06-170
OAAI
Goyal, Lipika; Meric-Bernstam, Funda; Hollebecque, Antoine; Valle, Juan W.; Morizane, Chigusa; Karasic, Thomas B.; Abrams, Thomas A.; Furuse, Junji; Kelley, Robin Katie; Cassier, Philippe A.; Klumpen, Heinz-Josef; Chang, Heung-Moon; Chen, Li-Tzong; Tabernero, Josep; Oh, Do-Youn; Mahipal, Amit; Moehler, Markus; Komatsu, Yoshito; Ahn, Daniel H.; Epstein, Robert S.; Halim, Abdel-Baset; Wacheck, Volker; He, Yaohua; Liu, Mei; Benhadji, Karim A.; Bridgewater, John A.
Germline mutations of homologous recombination genes and clinical outcomes in pancreatic cancer: a multicenter study in Taiwan

胰腺癌同源重组基因的种系突变和临床结果: 台湾的多中心研究

JOURNAL OF BIOMEDICAL SCIENCE
IF12.1
2024-02-134
OAAI
Cheng, Siao Muk; Su, Yung-Yeh; Chiang, Nai-Jung; Wang, Chih-Jung; Chao, Ying-Jui; Huang, Chien-Jui; Tsai, Hui-Jen; Chen, Shang-Hung; Chang, Chi-Yen; Tsai, Chia-Rung; Li, Yi-Jie; Yen, Chia-Jui; Chuang, Shih-Chang; Chang, Jeffrey Shu-Ming; Shan, Yan-Shen; Hwang, Daw-Yang; Chen, Li-Tzong

研究方向

暂未获取到该数据
Y
Yan‐Shen Shan
H 指数:41论文数:374被引数:7,542
N
Nai‐Jung Chiang
H 指数:22论文数:150被引数:1,501
J
Jen‐Shi Chen
H 指数:44论文数:307被引数:2.4万
A
Ann‐Lii Cheng
H 指数:102论文数:1,290被引数:7.6万
J
Jang‐Yang Chang
H 指数:56论文数:377被引数:8,937
Y
Yung‐Yeh Su
H 指数:13论文数:70被引数:424
H
Hui‐Jen Tsai
H 指数:18论文数:100被引数:885
K
Kun‐Huei Yeh
H 指数:50论文数:396被引数:1.5万
D
Do‐Youn Oh
H 指数:81论文数:950被引数:4.3万
L
Li‐Yuan Bai
H 指数:26论文数:230被引数:4,155